Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors

NCT04324372 | Completed Phase 1

• 1 other identifier: HEC68498-P-01
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical study of HEC68498 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of HEC68498 in patients with advanced refractory solid tumors

Conditions

Advanced Refractory Solid Tumors

Outcome Measures

Primary Outcomes (1)

• Maximum tolerated dose

  Patients will receive study drug on a daily basis for 28 days according to the dose and schedule specified for a particular cohort of therapy. Toxicities observed in Cycle 0\&1 will be considered for dose limiting toxicity (DLT) and Maximum tolerated dose (MTD)determination

  28 days

Secondary Outcomes (8)

• Number of subject with adverse events

  up to 4 weeks after last dose

• Objective response

  up to approximately 24 months

• AUC0-∞

  up to approximately 4 weeks

• AUC0-t

  up to approximately 4 weeks

• Cmax

  up to approximately 4 weeks

Study Arms (1)

HEC68498

EXPERIMENTAL

HEC68498 will be administered daily

Drug: HEC68498

Interventions

HEC68498 DRUG

HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.

HEC68498

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• （1）Target subjects
• years of age ≤ age ≤ 70 years of age, regardless of gender;
• Patients with various types of advanced solid tumors confirmed by cytological or histological examination.
• Dose escalation test phase: including breast cancer, colorectal cancer, neuroendocrine tumors, etc .; Extended trial phase: limited to patients with HR + / HER2-, triple-negative, breast, colorectal, and neuroendocrine tumors, and patients with HR + / HER2- and colorectal cancer need genetic testing (blood and / or tumor tissue) PIK3CA mutations have been confirmed. Patients with triple negative breast cancer need genetic testing (blood and / or tumor tissue) to confirm PIK3CA / PTEN- mutations.
• Requires at least standard treatment failure or no standard treatment. Definition of treatment failure: a. Disease progression during or after treatment must have clear imaging or clinical evidence; b. Withdrawal from treatment due to intolerable response.
• According to the solid tumor evaluation criteria (RECIST 1.1), there is at least one measurable lesion.
• Relieve from previous chemotherapy, hormone therapy, targeted therapy, radiotherapy or surgical treatment of toxic reactions (according to CTCAE v5.0 grading ≤ 1 except hair loss)
• ECOG score is 0 or 1 (see Annex 2 for ECOG score criteria);
• Expected survival time ≥ 12 weeks;
• (2) The subject must have proper organ function
• Blood routine: absolute neutrophil (ANC) ≥ 1.5 × 109 / L; platelet (PLT) ≥ 75 × 109 / L; hemoglobin (Hb) ≥ 90 g / L; Have received hematopoietic cell colony-stimulating growth factors (eg G-CSF, GM-CSF) or have not received blood transfusions. Erythropoietin or erythropoietin therapy can be maintained if it is used immediately before enrollment.
• Liver function: ALT and AST ≤ 2.5 × ULN (for patients with liver metastases, ALT and AST can be relaxed to ≤ 5.0 × ULN); serum bilirubin ≤ 1.5 × ULN;
• Renal function: serum creatinine ≤ 1.5 × ULN; or creatinine clearance (CrCl) ≥ 60 mL / min calculated according to the Cockcroft-Gault formula:
• Urine routine urinary protein ≤ 1+; if urinary routine urinary protein ≥ 2+, a 24-hour urine protein quantification is less than 1 g.
• Electrolyte: LLN ≤ blood potassium ≤ ULN;

You may not qualify if:

• (1) previous treatment history
• Have previously been treated with PI3K inhibitors, mTOR inhibitors (such as everolimus) or AKT inhibitors.
• Patients who have received targeted therapy within 4 weeks before the first dose or ≤ 5 × drug half-life (if the half-life of the drug is specified, it is calculated as 5 times the half-life, otherwise 4 weeks);
• Patients who have received chemotherapy, hormonal antitumor therapy, immunotherapy or major surgery within 4 weeks before the first dose.
• Note: If the previous treatment was nitrosourea or mitomycin, the treatment must be discontinued at least 6 weeks before the first study drug is administered.
• Patients who have received radiation therapy within 4 weeks before the first dose.
• Have received clinical trial drug treatment within 4 weeks before the first medication, or are receiving other clinical trial drug treatment;
• (2) History of disease and surgery
• CNS metastases requiring current treatment or uncontrolled CNS metastases; or CNS metastases confirmed but not stable for more than 4 weeks after treatment;
• Patients with spinal cord compression, cancerous meningitis, or meningitis;
• Currently diagnosed with type I or type II diabetes or fasting blood glucose levels\> 6.7 mmol / L, or HbA1c\> 7%;
• Patients with hypertension controlled by two or more drugs, or uncontrolled hypertension (systolic blood pressure\> 140 mmHg or diastolic blood pressure\> 90 mmHg);
• Left ventricular ejection fraction (LVEF) \<50%; QTcF\> 450 ms for men, QTcF\> 470 ms for women (QTcF is calculated using Fridericia's correction formula QTcF = QT / RR 0.33); any room with obvious clinical significance History of arrhythmia (such as ventricular tachycardia, ventricular fibrillation, torsional ventricular tachycardia or frequent ventricular premature beats, congenital prolonged QT interval syndrome).
• Multiple factors affecting oral medication (eg, inability to swallow, chronic diarrhea, and intestinal obstruction, etc.);
• Patients with a clear tendency to gastrointestinal bleeding, including the following: local active ulcer lesions and positive fecal occult blood; those with a history of melena and vomiting within 2 months before the first medication; researchers believe that digestion may occur Major bleeding

Sponsors & Collaborators

• Sunshine Lake Pharma Co., Ltd.: lead

Study Sites (1)

The Fifth Medical Center of PLA Ceneral Hospital

Beijing, China/BEIJING, 100071, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 18, 2020
• First Posted: March 27, 2020
• Study Start: February 27, 2019
• Primary Completion: February 26, 2021
• Study Completion: March 26, 2021
• Last Updated: August 12, 2022

Record last verified: 2022-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)